Study of Cannabinoid Drug for Osteoarthritis Continues Even After Failed Phase 2 Trial

Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis.

Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel). The study did not meet its primary endpoint of reduction from baseline in the weekly mean of the 24-hour average worst pain score at week 12 for either dose. However, statistically significant results were achieved for a number of secondary endpoints. Importantly, the composite responder analysis (defined as a ≥30 percent reduction in worst average daily pain scores and a ≥20 percent improvement in the WOMAC physical function score) for 250 mg daily of ZYN002 4.2% CBD gel achieved statistical significance (p=0.016). A trend toward statistical significance was

... read more at: https://www.pharmpro.com/news/2017/08/study-cannabinoid-drug-osteoarthritis-continues-even-after-failed-phase-2-trial

by